StockData
LENSAR, Inc. logo

LENSAR, Inc. (LNSR) stock analysis

LNSRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/3016% below fair value
$5.29+0.29 (+5.80%)

Close on Nov 16, 2026Market cap $64.99MP/E –Yield –

StockData Score

Prices as of Nov 16, 2026How the score works

Value1Growth2Performance2Health2Dividend0

Weak7 of 30 checks passed

Lensar passes 7 of the 30 checks behind our score; 17 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
1/6
Growth
2/6
Past performance
2/6
Financial health
2/6
Dividend
0/6

What stands out

  • Trading below fair value

    The share price of $5.29 is below our fair value estimate of $6.28.

  • Low debt

    Debt is 25.2% of shareholders' equity, under the 40% we consider low.

  • Revenue growing 10%+ a year

    Revenue grew 18.2% a year over the last three fiscal years.

  • Gross margin improving

    Gross margin was 48.3% over the last twelve months, against 47.2% a year earlier.

What to watch

  • Margin of safety under 20%

    The price is 15.8% below fair value, less than the 20% cushion we look for.

  • Debt not well covered by cash flow

    Operating cash flow over the last twelve months equals -194% of total debt; we look for at least 20%.

  • Elevated bankruptcy risk

    The Altman Z-score is -0.86; above 3 is the safe zone and below 1.8 the distress zone.

  • P/B above the industry

    Lensar's price-to-book of 4.36 is above the Surgical, Medical, and Dental Instruments and Supplies median of 3.27.

Valuation1/6
  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B above the industry

    Lensar's price-to-book of 4.36 is above the Surgical, Medical, and Dental Instruments and Supplies median of 3.27.

  • Trading below fair value

    The share price of $5.29 is below our fair value estimate of $6.28.

  • Margin of safety under 20%

    The price is 15.8% below fair value, less than the 20% cushion we look for.

Growth2/6
  • Revenue growing 10%+ a year

    Revenue grew 18.2% a year over the last three fiscal years.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing slower than the industry

    Revenue grew 3.3% over the last twelve months; the Surgical, Medical, and Dental Instruments and Supplies median is 10.4%.

  • Company guidance

    No outlook found in earnings releases from the last twelve months.

  • Gross margin improving

    Gross margin was 48.3% over the last twelve months, against 47.2% a year earlier.

Past performance2/6
  • Return on equity

    Needs positive equity and five years of results.

  • Return on invested capital

    Needs operating income and invested capital.

  • Return on equity against the industry

    Needs positive equity.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin above its 5-year average

    Net margin was 57.6% over the last twelve months, against a 5-year average of -52.9%.

  • Net margin above the industry

    Lensar's net margin of 57.6% is above the Surgical, Medical, and Dental Instruments and Supplies median of -14.8%.

Financial health2/6
  • Low debt

    Debt is 25.2% of shareholders' equity, under the 40% we consider low.

  • Debt trend

    Needs a balance sheet from five years ago with positive equity.

  • Debt not well covered by cash flow

    Operating cash flow over the last twelve months equals -194% of total debt; we look for at least 20%.

  • Interest coverage

    Interest expense is not reported separately.

  • Short-term assets cover short-term debts

    Current assets are 2.39 times current liabilities.

  • Elevated bankruptcy risk

    The Altman Z-score is -0.86; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6
  • No dividend

    Lensar has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Our estimate per share

$6.28

The share price is 16% below this estimate.

20%+ below
Near fair value
20%+ above
$5.29Price$6.28Fair value
MethodMultiple usedOwn 5Y medianIndustry medianValue per shareWeight
P/B2.3×1.4×3.3×$2.8350%
P/S2.0×1.4×2.6×$9.7350%
Fair value$6.28100%

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/B at month end
  • Own 5-year median 1.4
  • Surgical, Medical, and Dental Instruments and Supplies median 3.3

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

High risk

Average value traded per day
$334.19K
Value traded per 1% price move
$148.62K

Downside

High risk

Typical loss in a bad month
52.2%
Volatility (annualized)
69%
Sharpe ratio, 1 year
-0.77
Beta to the S&P 500 (5Y)
1.50

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2018 to 2025

Gross margin

46.4%−6.9 pts over 5 years

Operating margin

-42.1%+28.1 pts over 5 years

Net margin

-58.7%+16.3 pts over 5 years

See a number that looks wrong?